This article is an independent overview of advancements in the treatment of atopic dermatitis, based on recent clinical studies. It is intended to provide healthcare professionals with up-to-date, evidence-based information.
Atopic dermatitis (AD) is a prevalent, chronic inflammatory skin condition characterized by intense itch, pain, sleep disturbances, and psychosocial effects such as anxiety and depression, which often result in an increase in healthcare utilization. When topical treatments fail to adequately manage the disease, systemic therapies are recommended.1,2
In recent years, two new classes of systemic therapies have emerged: monoclonal antibodies targeting the type 2 inflammatory pathway and small-molecule inhibitors that block signalling not only in type 2 pathways but also in other cytokine-mediated processes.2 With the availability of these therapies, head-to-head clinical studies are crucial in guiding healthcare professionals on the optimal use of these treatments in clinical practice.2
Login to read more
